Spectrum Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
SPPI Spectrum Pharmaceuticals Inc
FDBC Fidelity D&D Bancorp Inc
$BUKCHET Bloomberg Coffee Subindex Euro
BMY Bristol-Myers Squibb Co
MLGO MicroAlgo Inc
FRST Primis Financial Corp
VII 7GC & Holdings Co Inc
PEBO Peoples Bancorp Inc
BIOAF Bioasis Technologies Inc
NRGOF Newrange Gold Corp
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology | Small Cap Value
Company profile

Spectrum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing, and commercializing targeted oncology therapies. The Company's product portfolio consists of in-development drug products for the treatment of cancer patients. The Company's pipeline products include Eflapegrastim and Poziotinib. The Eflapegrastim is a long-acting granulocyte colony-stimulating factor (G-CSF) for chemotherapy-induced neutropenia. Poziotinib is a, pan-HER inhibitor that irreversibly blocks signaling through the Epidermal Growth Factor Receptor (EGFR) family of tyrosine-kinase receptors, including HER1 (erbB1; EGFR), HER2 (erbB2), HER4 (erbB4), and HER receptor mutations. The Eflapegrastim employs a LAPSCOVERY technology to enhance the duration of therapeutic effects and reduce the frequency of administration.

Closing Price
$0.8198
Day's Change
0.0098 (1.21%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.83
Day's Low
0.7988
Volume
(Light)
Volume:
1,129,883

10-day average volume:
2,318,281
1,129,883

Credit Suisse strikes deal to sell securitized-products group to Apollo

1:44 am ET November 15, 2022 (MarketWatch)
Print

By Mauro Orru

Credit Suisse Group AG has entered into definitive transaction agreements to sell a large part of its securitized-products group and other financing businesses to Apollo Global Management Inc. as it seeks to derisk its investment bank and divert capital to its core businesses.

The Swiss lender (CSGN.EB) said Tuesday that the deal with Apollo and the sale of other assets to third-party investors would slash the value of assets under its securitized-products group to roughly $20 billion from $75 billion through several transactions that Credit Suisse expects to be close by mid-2023.

Apollo will manage those remaining assets under an investment relationship with an expected term of five years to be agreed upon at the first closing.

The transactions should hand Credit Suisse a release of risk weighted assets of up to $10 billion, strengthening its capital ratio.

The Wall Street Journal reported last month that the bank was nearing a deal to sell its securitized-products group, citing people familiar with the matter.

Credit Suisse plans to cut thousands of jobs and raise around $4 billion in fresh capital in a move to turn a page on a chapter of scandals, hefty losses, executive turnover and waning market confidence.

Write to Mauro Orru at mauro.orru@wsj.com; @MauroOrru94

-Mauro Orru

	

(END) Dow Jones Newswires

November 15, 2022 01:44 ET (06:44 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.